Hologic (NASDAQ:HOLX) Releases FY 2025 Earnings Guidance

Hologic (NASDAQ:HOLX) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of 4.250-4.350 for the period, compared to the consensus estimate of 4.250. The company issued revenue guidance of $4.1 billion-$4.1 billion, compared to the consensus revenue estimate of $4.2 billion. Hologic also updated its Q2 2025 guidance to 1.000-1.030 EPS.

Hologic Stock Performance

HOLX stock traded up $1.22 during midday trading on Wednesday, reaching $72.80. 2,779,067 shares of the company’s stock traded hands, compared to its average volume of 2,293,025. Hologic has a 52 week low of $68.61 and a 52 week high of $84.67. The company has a 50-day moving average price of $73.05 and a two-hundred day moving average price of $77.98. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The firm has a market capitalization of $16.43 billion, a PE ratio of 21.86, a price-to-earnings-growth ratio of 2.35 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. As a group, equities analysts anticipate that Hologic will post 4.28 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on HOLX shares. Royal Bank of Canada boosted their price target on shares of Hologic from $86.00 to $89.00 and gave the company a “sector perform” rating in a research report on Tuesday, November 5th. Jefferies Financial Group began coverage on Hologic in a research note on Tuesday, December 10th. They issued a “hold” rating and a $85.00 target price on the stock. William Blair restated an “outperform” rating on shares of Hologic in a research report on Monday, January 13th. UBS Group lifted their target price on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Finally, Morgan Stanley dropped their price objective on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Eight research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $88.92.

Insider Buying and Selling at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.88% of the stock is currently owned by corporate insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.